Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of JNJ-42847922 in Hepatic Impairment
NCT04960124Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of seltorexant in major depressive disorder (MDD) and Insomnia (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Analyte Concentration, Area Under Plasma Analyte Concentration versus Time Curve from Time Zero to Time of Last Measurable Concentration and 1 more. Started Aug 2021; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT04960124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04960124.